GlassScriptPhysician profile
Hayama Brill
NPI 1831397082
$2,070.57
in general payments reported to CMS, 2019-2025
16 companies · $21.71 in 2025
The $21.71 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $375 · 2021: $163 · 2022: $85.17 · 2023: $65.57 · 2024: $145 · 2025: $21.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.39 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.64 | 2019-2022 | |
| Celularity INC. | $600.00 | 2019-2020 | |
| Therapeuticsmd, INC. | $258.14 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $131.16 | 2019 | |
| Astellas Pharma US INC | $120.63 | 2024 | Veozah |
| Roche Diagnostics Corporation | $67.97 | 2019 | |
| Sumitomo Pharma America, INC. | $65.57 | 2023 | Myfembree |
| Daiichi Sankyo INC. | $34.03 | 2019-2021 | |
| Shield Therapeutics INC | $24.48 | 2024 | |
| Glaxosmithkline, LLC. | $21.71 | 2025 | Nucala |
| Amag Pharmaceuticals, INC. | $20.99 | 2019 | |
| Myovant Sciences INC. | $19.93 | 2021 | |
| Lupin INC. | $18.76 | 2019 | |
| Evofem Biosciences, INC. | $17.74 | 2022 | |
| Hologic Sales and Service, LLC | $17.45 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayama Brill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.